Sulopenem Etzadroxil

Summary

Sulopenem Etzadroxil (CHEMBL4594246) is an approved small molecule; indicated across 4 conditions including urinary tract infection and cystitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 477.6 Da · C19H27NO7S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594246
Name	Sulopenem Etzadroxil
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	49785800
Molecular formula	C19H27NO7S3
Molecular weight	477.6
InChIKey	NBPVNGWRLGHULH-JKOUTOBWSA-N

SMILES: CCC(CC)C(=O)OCOC(=O)C1=C(S[C@H]2N1C(=O)[C@@H]2[C@@H](C)O)S[C@H]3CCS(=O)C3

IUPAC name: 2-ethylbutanoyloxymethyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

Also known as: PF-03709270, PF03709270, Sulopenem etzadroxil, SULOPENEM ETZADROXIL

Patent coverage: 11 distinct patent families (34 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	3	MONDO:0100338	EFO:0003103
cystitis	3	MONDO:0006032	EFO:1000025
pneumonia	1	MONDO:0005249	EFO:0003106

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	2
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05584657	PHASE3	COMPLETED	Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women
NCT00797108	PHASE2	COMPLETED	A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
NCT07092813	PHASE1	RECRUITING	Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
NCT00759564	PHASE1	COMPLETED	A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
NCT04682834	Not specified	NO_LONGER_AVAILABLE	Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).